Contribution of germline mutations in BRCA2, P16INK4a, P14ARF and P15 to uveal melanoma

Investigative Ophthalmology and Visual Science

Volumn 44, Issue 2, 2003, Pages 458-462

  Hearle, Nicholas ^a   Damato, Bertil E ^b   Humphreys, Jane ^a   Wixey, Julie ^a   Green, Helen ^b   Stone, Joanne ^a   Easton, Douglas F ^c   Houlston, Richard S ^a,d  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d Haddow Laboratories   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; BRCA2 PROTEIN; GLYCINE; PROTEIN P14; PROTEIN P15; PROTEIN P16;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BREAST CANCER; EXON; FEMALE; GENE LOCUS; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GERM LINE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; RISK FACTOR; UVEA MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; BRCA2 PROTEIN; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GERM-LINE MUTATION; HUMANS; INCIDENCE; MALE; MELANOMA; MIDDLE AGED; POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEINS; UVEAL NEOPLASMS;

EID: 0037311133     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.02-0026     Document Type: Article

References (54)

1. Parkin DM, Muir CS, Whelan LB. Cancer Incidence in Five Countries. Vol 6. International Agency for Research on Cancer. Lyon, France, 1992.
2. Dolin PJ, Johnson GJ. Solar ultraviolet radiation and ocular disease: a review of the epidemiological and experimental evidence. Ophthalmic Epidemiol. 1994;1:155-164.
3. Canning CR, Hungerford J. Familial uveal melanoma. Br J Ophthalmol. 1988;72:241-243.
4. Jay M, McCartney AC. Familial malignant melanoma of the uvea and p53: a Victorian detective story. Surv Ophthalmol. 1993;37:457-462.
5. Lynch HT, Anderson DE, Krush AJ. Heredity and intraocular malignant melanoma: study of two families and review of forty-five cases. Cancer. 1968;21:119-125.
6. Singh AD, Wang MX, Donoso LA, et al. Familial uveal melanoma. III. Is the occurrence of familial uveal melanoma coincidental? Arch Ophthalmol. 1996;114:1101-1104.
7. Singh AD, Shields CL, De Potter P, et al. Familial uveal melanoma: clinical observations on 56 patients. Arch Ophthalmol. 1996;114:392-399.
8. Singh AD, Shields CL, Shields JA, De Potter P. Bilateral primary uveal melanoma: bad luck or bad genes? Ophthalmology. 1996; 103:256-262.
9. Tucker MA, Boice JD Jr, Hoffman DA. Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Connecticut, 1935-82. Natl Cancer Inst Monogr. 1985;68:161-189.
10. Travis LB, Curtis RE, Boice JD Jr, Platz CE, Hankey BF, Fraumeni JF Jr. Second malignant neoplasms among long term survivors of ovarian cancer. Cancer Res. 1996;56:1564-1570.
11. Osterlind A, Olsen JH, Lynge E, Ewertz M. Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Denmark, 1943-80. Natl Cancer Inst Monogr. 1985;68:361-388.
12. Schoenberg BS, Christine BW. Malignant melanoma associated with breast cancer. South Med J. 1980;73:1493-1497.
13. Hemminki K, Jiang Y. Association of ocular melanoma with breast cancer but not with cutaneous melanoma: results from the Swedish Family-Cancer Database. Int J Cancer. 2001;94:907-909.
14. Mullaney J, Mooney D, O'Connor M, McDonald GS. Bilateral ovarian carcinoma with bilateral uveal melanoma. Br J Ophthalmol. 1984;68:261-267.
15. van Hees CL, Jager MJ, Bleeker JC, Kemme H, Bergman W. Occurrence of cutaneous and uveal melanoma in patients with uveal melanoma and their first degree relatives. Melanoma Res. 1998;8:175-180.
16. Bataille V, Pinney E, Hungerford JL, Cuzick J, Bishop DT, Newton JA. Five cases of coexisting primary ocular and cutaneous melanoma. Arch Dermatol. 1993;129:1998-1201.
17. Bataille V, Sasieni P, Cusick J, Hungerford JL, Swerdlow A, Newton-Bishop JA. Risk of ocular melanoma in relationship to cutaneous and iris naevi. Int J Cancer. 1995;60:622-626.
18. Gruis NA, van der Velden PA, Bergman W, Frants RR. Familial melanoma: CDKN2A and beyond. J Invest Dermatol Symp Proc. 1999;4:50-54.
19. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704-707.
20. Stott FJ, Bates S, James MC, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998;17:5001-5014.
21. Zuo L, Weger J, Yang Q, Goldstein AM, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet. 1996;12:97-99.
22. Soufir N, Avril MF, Chompret A, et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France: The French Familial Melanoma Study Group. Hum Mol Genet. 1998;7:209-216.
23. Stone S, Dayananth P, Jiang P, et al. Genomic structure, expression and mutational analysis of the P15 (MTS2) gene. Oncogene. 1995; 11:987-991.
24. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science. 1992;258:1148-1152.
25. Speicher MR, Prescher G, du Manoir S, et al. Chromosomal gains and losses in uveal melanomas detected by comparative genomic hybridization. Cancer Res. 1994;54:3817-3823.
26. Ohta M, Nagai H, Shimizu M, et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res. 1994;54:5269-5272.
27. Merbs SL, Sidransky D. Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma. Invest Ophthalmol Vis Sci. 1999;40:779-783.
28. van der Velden PA, Metzelaar-Blok JA, Bergman W, et al. Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma. Cancer Res. 2001;61:5303-5306.
29. Easton DF, Steele L, Fields P, et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet. 1997;61:120-128.
30. Marghoob AA. The dangers of atypical mole (dysplastic nevus syndrome). Postgrad Med. 1999;105:147-154.
31. Hodgson SV, Maher ER. A practical guide to human cancer genetics. 2nd ed. Cambridge, UK: Cambridge University Press; 1999:138.
32. Kote-Jarai Z, Easton D, Edwards SM, et al. Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer. Pharmacogenetics. 2001;11:325-330.
33. Ganguly A, Rock MJ, Prockop DJ. Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci USA. 1993;90:10325-10329.
34. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789-792.
35. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet. 1994;8:15-21.
36. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436-440.
37. FitzGerald MG, Harkin DP, Silva-Arrieta S, et al. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci USA. 1996;93:8541-8545.
38. Genbank. National Center for Biotechnology Information, Bethesda, MD; available at http://www.ncbi.nlm.nih.gov/Genbank/. Accessed August 10, 2002.
39. Breast Cancer Information Core Mutation databases. National Center for Biotechnology Information, Bethesda, MD; available at http://research.nhgri.nih.gov/projects/bic/. Accessed August 10, 2002.
40. Human Gene Mutation Database. Institute of Medical Genetics, University of Wales College of Medicine, Cardiff, Wales, UK; available at http://archive.uwcm.ac.uk/uwcm/mg. Accessed August 10, 2002.
41. ClustalW (ver. 1.82) multiple sequence alignment program. European Bioinformatics Institute, European Molecular Biology Laboratory, Heidelberg, Germany; available at http://www.ebi.ac.uk/clustalw/. Accessed August 10, 2001.
42. Soufir N, Bressac-de Paillerets B, Desjardins L, et al. Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes. Br J Cancer. 2000;82:818-822.
43. Walker GJ, Hussussian CJ, Flores JF, et al. Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet. 1995;4:1845-1852.
44. Bishop DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst. 2002;94:894-903.
45. Wang X, Egan KM, Gragoudas ES, Kelsey KT. Constitional alterations in p16 in patients with uveal melanoma. Melanoma Res. 1996;6:405-410.
46. Singh AD, Croce CM, Wary KK, et al. Familial uveal melanoma: absence of germline mutations involving the cyclin-dependent kinase-4 inhibitor gene (p16). Ophthalmic Genet. 1996;17:39-40.
47. Peto J, Collins N, Barfoot R, Seal S, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999;91:943-949.
48. Sinilnikova OM, Egan KM, Quinn JL, et al. Germline brca2 sequence variants in patients with ocular melanoma Int J Cancer. 1999;82:325-328.
49. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91:1310-1316.
50. Bahuau M, Vidaud D, Jenkins RB, et al. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res. 1998;58:2298-2303.
51. Randerson-Moor JA, Harland M, Williams S, et al. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet. 2001;10:55-56.
52. Tsao H, Benoit E, Sober AJ, Thiele C, Haluska FG. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene. Cancer Res. 1998;58:109-113.
53. Puig S, Ruiz A, Lazaro C, et al. Chromosome 9p deletions in cutaneous malignant melanoma tumors: the minimal deleted region involves markers outside the p16 (CDKN2) gene. Am J Hum Genet. 1995;57:395-402.
54. Liu L, Goldstein AM, Tucker MA, et al. Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF. Genes Chromosomes Cancer. 1997; 19:52-54.